About

HiFiBiO Therapeutics, a clinical stage US biotech with global footprint headquartered in Cambridge, MA, is pioneering a unique high-resolution translational platform (DIS®) to enhance the probability of success for therapies.

Our Vision

Unlock the curative powers of the immune system
for each and every patient

Our Mission

Build an industry leading immune modulation biotech to deliver transformative medicines

Our Strategy

Advance a sustainable pipeline of breakthrough immunotherapies using DIS®, a paradigm shifting single cell translational approach

Our Team

Leadership Team

Liang Schweizer, Ph.D.
Founder, Chairperson and CEO
Francisco Adrian, Ph.D.
Chief Scientific Officer
Robert Andtbacka, M.D., C.M.
Chief Medical Officer
John Pallante
Senior Vice President, Global Head of Clinical Operations and Quality Management
Jinping Gan, Ph.D.
Vice President, Head of Translational Medicine
Alexandre Grassin
Vice President, Finance
Edward Rocnik, Ph.D.
Executive Director, Head of CMC
Steven Chen, J.D., Ph.D.
General Counsel
Roshan Kumar, Ph.D.
Executive Director, Head of Research
Pascaline Mary, PhD
Senior Director, Head of Single Cell Science
Vincent Tse, MBA
Senior Director, Staff and Strategy
Timothy Miller, MSc
Senior Director, Business Development

Aurélien Marabelle, MD, PhD

Senior Medical Oncologist in the Drug Development Department and the Clinical Director of Cancer Immunotherapy Program at Gustave Roussy

See full bio

Giovanni Abbadessa, MD, PhD

Vice President, Head of Oncology Early Development at Sanofi-Genzyme

See full bio

Leslie Kean, MD, PhD

Director of the Stem Cell Transplantation Program and Physician at Dana-Farber/Boston Children’s Cancer Center and Blood Disorders Center

See full bio

Michael Croft, PhD

Director of Scientific Affairs, Professor for the Center of Autoimmunity and Inflammation at La Jolla Institute for Immunology                                                      

See full bio

Peter Ho, MD, PhD

Former CMO at Boston Pharmaceuticals, Former CMO at Epizyme, Former President and Co-Founder at BeiGene, Former VP of Oncology Development at J&J

See full bio

Sebastian Amigorena, PhD

Director of the INSERM Immunity & Cancer Lab, and Head of Immunology and Immunotherapy department at Institut Curie

See full bio

Wendye Robbins, MD

President and CEO of Incendia Therapeutics, Former CEO of Blade Therapeutics, Former CEO of Limerick Biopharma

See full bio

Andrew Griffiths, PhD

Professor of Biochemistry at École Supérieure de Chimie Industrielles de Paris (ESPCI) in Paris

Bradley Bernstein, MD, PhD

Director of Gene Regulation Observatory at the Broad Institute of MIT and Harvard

David Weitz, PhD

Mallinckrodt Professor of Physics & Applied Physics and professor of Systems Biology at Harvard University

Jérôme Bibette, PhD

Professor of soft matter physics at École Supérieure de Chimie Industrielles de Paris (ESPCI)

Robert Nicol, PhD

Venture Partner at RA Capital Management

Our Team

Leadership Team

Liang Schweizer, Ph.D.
Founder, Chairperson and CEO
Francisco Adrian, Ph.D.
Chief Scientific Officer
Robert Andtbacka, M.D., C.M.
Chief Medical Officer
John Pallante
Senior Vice President, Global Head of Clinical Operations and Quality Management
Jinping Gan, Ph.D.
Vice President, Head of Translational Medicine
Alexandre Grassin
Vice President, Finance
Edward Rocnik, Ph.D.
Executive Director, Head of CMC
Steven Chen, J.D., Ph.D.
General Counsel
Roshan Kumar, Ph.D.
Executive Director, Head of Research
Pascaline Mary, PhD
Senior Director, Head of Single Cell Science
Vincent Tse, MBA
Senior Director, Staff and Strategy
Timothy Miller, MSc
Senior Director, Business Development

Aurélien Marabelle, MD, PhD

Senior Medical Oncologist in the Drug Development Department and the Clinical Director of Cancer Immunotherapy Program at Gustave Roussy

See full bio

Giovanni Abbadessa, MD, PhD

Vice President, Head of Oncology Early Development at Sanofi-Genzyme

See full bio

Leslie Kean, MD, PhD

Director of the Stem Cell Transplantation Program and Physician at Dana-Farber/Boston Children’s Cancer Center and Blood Disorders Center

See full bio

Michael Croft, PhD

Director of Scientific Affairs, Professor for the Center of Autoimmunity and Inflammation at La Jolla Institute for Immunology                                                      

See full bio

Peter Ho, MD, PhD

Former CMO at Boston Pharmaceuticals, Former CMO at Epizyme, Former President and Co-Founder at BeiGene, Former VP of Oncology Development at J&J

See full bio

Sebastian Amigorena, PhD

Director of the INSERM Immunity & Cancer Lab, and Head of Immunology and Immunotherapy department at Institut Curie

See full bio

Wendye Robbins, MD

President and CEO of Incendia Therapeutics, Former CEO of Blade Therapeutics, Former CEO of Limerick Biopharma

See full bio

Andrew Griffiths, PhD

Professor of Biochemistry at École Supérieure de Chimie Industrielles de Paris (ESPCI) in Paris

Bradley Bernstein, MD, PhD

Director of Gene Regulation Observatory at the Broad Institute of MIT and Harvard

David Weitz, PhD

Mallinckrodt Professor of Physics & Applied Physics and professor of Systems Biology at Harvard University

Jérôme Bibette, PhD

Professor of soft matter physics at École Supérieure de Chimie Industrielles de Paris (ESPCI)

Robert Nicol, PhD

Venture Partner at RA Capital Management

Our Investors

We are funded by leading VC firms focused on transforming patient care including Mirae Asset, B Capital Group, IDG Capital, Kite Pharma, Sequoia Capital, LYFE Capital, etc

Open-Innovation Partnerships

We continue to establish strategic partnerships with leading pharmaceutical and biotechnology companies, as well as academic institutions to help allocate resources more efficiently, expand DIS® applications and accelerate pipeline commercialization. All our collaborations are architected for speed and driven by our scientific strategy.